Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta‐analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Htut, Thura W., Thein, Kyaw Z., Lawrie, Alastair, Tighe, Jane, Preston, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175766/
https://www.ncbi.nlm.nih.gov/pubmed/35847725
http://dx.doi.org/10.1002/jha2.46
_version_ 1784722519787307008
author Htut, Thura W.
Thein, Kyaw Z.
Lawrie, Alastair
Tighe, Jane
Preston, Gavin
author_facet Htut, Thura W.
Thein, Kyaw Z.
Lawrie, Alastair
Tighe, Jane
Preston, Gavin
author_sort Htut, Thura W.
collection PubMed
description The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta‐analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab‐treated cohorts (HR 0.46, 95% CI 0.38‐0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high‐risk cytogenetics and this group remains a therapeutic challenge.
format Online
Article
Text
id pubmed-9175766
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91757662022-07-14 Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials Htut, Thura W. Thein, Kyaw Z. Lawrie, Alastair Tighe, Jane Preston, Gavin EJHaem Short Reports The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta‐analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab‐treated cohorts (HR 0.46, 95% CI 0.38‐0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high‐risk cytogenetics and this group remains a therapeutic challenge. John Wiley and Sons Inc. 2020-06-23 /pmc/articles/PMC9175766/ /pubmed/35847725 http://dx.doi.org/10.1002/jha2.46 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Htut, Thura W.
Thein, Kyaw Z.
Lawrie, Alastair
Tighe, Jane
Preston, Gavin
Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title_full Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title_fullStr Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title_full_unstemmed Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title_short Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
title_sort efficacy of daratumumab combination regimen in patients with multiple myeloma: a combined analysis of phase iii randomized controlled trials
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175766/
https://www.ncbi.nlm.nih.gov/pubmed/35847725
http://dx.doi.org/10.1002/jha2.46
work_keys_str_mv AT htutthuraw efficacyofdaratumumabcombinationregimeninpatientswithmultiplemyelomaacombinedanalysisofphaseiiirandomizedcontrolledtrials
AT theinkyawz efficacyofdaratumumabcombinationregimeninpatientswithmultiplemyelomaacombinedanalysisofphaseiiirandomizedcontrolledtrials
AT lawriealastair efficacyofdaratumumabcombinationregimeninpatientswithmultiplemyelomaacombinedanalysisofphaseiiirandomizedcontrolledtrials
AT tighejane efficacyofdaratumumabcombinationregimeninpatientswithmultiplemyelomaacombinedanalysisofphaseiiirandomizedcontrolledtrials
AT prestongavin efficacyofdaratumumabcombinationregimeninpatientswithmultiplemyelomaacombinedanalysisofphaseiiirandomizedcontrolledtrials

Ejemplares similares